6 August company perspectum Group, offering medical imaging software, withdrew the IPO application. The company planned to attract 75 million dollars, releasing 4,7 million shares at a price of 15 to 17 dollars.
Perspectum software products combine imaging, image analysis of magnetic resonance imaging (MRT) and artificial intelligence (II) to aid in the diagnosis, prescribing treatment and monitoring the development of chronic metabolic diseases, multiple organ pathologies and cancer, as well as determining the patient's response to treatment. The company's product line includes AI-powered cloud software, which uses medical imaging. The company's flagship AI product, LiverMultiScan, has been approved by the FDA for the non-invasive diagnosis and monitoring of liver disease, including non-alcoholic fatty liver disease and non-alcoholic steatohepatitis . The company's SaaS platform is currently available in approximately 350 centers around the world.
Company headquartered in Oxfordshire, Great Britain, was founded in 2012 year, and for 12 months, ended 31 Martha 2021 of the year, its revenue was 9 million dollars. The company planned to list on the exchange Nasdaq under the ticker SCAN. Citi was to become the joint organizers of the share issue, Barclays, Stifel и Canaccord Genuity.